Onsdag 30 Oktober | 09:28:00 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

Tid*
2026-02-19 14:00 Bokslutskommuniké 2025
2025-10-23 08:00 Kvartalsrapport 2025-Q3
2025-07-16 08:00 Kvartalsrapport 2025-Q2
2025-04-24 - Årsstämma
2025-04-24 08:00 Kvartalsrapport 2025-Q1
2025-02-19 14:00 Bokslutskommuniké 2024
2024-10-23 - Kvartalsrapport 2024-Q3
2024-07-16 - Kvartalsrapport 2024-Q2
2024-04-26 - X-dag ordinarie utdelning BIOT 1.60 SEK
2024-04-25 - Kvartalsrapport 2024-Q1
2024-04-25 - Årsstämma
2024-02-15 - Bokslutskommuniké 2023
2023-10-25 - Kvartalsrapport 2023-Q3
2023-07-17 - Kvartalsrapport 2023-Q2
2023-04-28 - X-dag ordinarie utdelning BIOT 1.60 SEK
2023-04-27 - Kvartalsrapport 2023-Q1
2023-04-27 - Årsstämma
2023-02-15 - Bokslutskommuniké 2022
2022-11-02 - Kvartalsrapport 2022-Q3
2022-07-19 - Kvartalsrapport 2022-Q2
2022-04-29 - X-dag ordinarie utdelning BIOT 1.55 SEK
2022-04-28 - Årsstämma
2022-04-28 - Kvartalsrapport 2022-Q1
2022-02-11 - Bokslutskommuniké 2021
2021-10-28 - Kvartalsrapport 2021-Q3
2021-07-16 - Kvartalsrapport 2021-Q2
2021-04-29 - X-dag ordinarie utdelning BIOT 1.50 SEK
2021-04-28 - Årsstämma
2021-04-28 - Kvartalsrapport 2021-Q1
2021-02-12 - Bokslutskommuniké 2020
2020-11-05 - Kvartalsrapport 2020-Q3
2020-07-17 - Kvartalsrapport 2020-Q2
2020-06-05 - X-dag ordinarie utdelning BIOT 0.00 SEK
2020-06-04 - Årsstämma
2020-04-28 - Kvartalsrapport 2020-Q1
2020-02-07 - Bokslutskommuniké 2019
2019-11-07 - Extra Bolagsstämma 2019
2019-11-05 - Kvartalsrapport 2019-Q3
2019-07-16 - Kvartalsrapport 2019-Q2
2019-04-25 - X-dag ordinarie utdelning BIOT 1.50 SEK
2019-04-24 - Kvartalsrapport 2019-Q1
2019-04-24 - Årsstämma
2019-02-07 - Bokslutskommuniké 2018
2018-11-06 - Kvartalsrapport 2018-Q3
2018-07-16 - Kvartalsrapport 2018-Q2
2018-04-27 - X-dag ordinarie utdelning BIOT 1.40 SEK
2018-04-26 - Kvartalsrapport 2018-Q1
2018-04-26 - Årsstämma
2018-02-08 - Bokslutskommuniké 2017
2017-11-02 - Kvartalsrapport 2017-Q3
2017-07-18 - Kvartalsrapport 2017-Q2
2017-04-28 - X-dag ordinarie utdelning BIOT 1.25 SEK
2017-04-27 - Årsstämma
2017-02-09 - Bokslutskommuniké 2016
2016-11-10 - Kvartalsrapport 2016-Q3
2016-08-11 - Kvartalsrapport 2016-Q2
2016-04-29 - X-dag ordinarie utdelning BIOT 1.00 SEK
2016-04-29 - X-dag bonusutdelning BIOT 0.25
2016-04-28 - Kvartalsrapport 2016-Q1
2016-04-28 - Årsstämma
2016-02-11 - Bokslutskommuniké 2015
2015-10-30 - Kvartalsrapport 2015-Q3
2015-08-13 - Kvartalsrapport 2015-Q2
2015-04-29 - X-dag ordinarie utdelning BIOT 0.75 SEK
2015-04-28 - Kvartalsrapport 2015-Q1
2015-04-28 - Årsstämma
2015-02-12 - Bokslutskommuniké 2014
2014-10-30 - Kvartalsrapport 2014-Q3
2014-08-14 - Kvartalsrapport 2014-Q2
2014-04-29 - X-dag ordinarie utdelning BIOT 0.60 SEK
2014-04-28 - Kvartalsrapport 2014-Q1
2014-04-28 - Årsstämma
2014-02-13 - Bokslutskommuniké 2013
2013-10-25 - Kvartalsrapport 2013-Q3
2013-08-15 - Kvartalsrapport 2013-Q2
2013-04-26 - X-dag ordinarie utdelning BIOT 0.50 SEK
2013-04-25 - Årsstämma
2013-04-25 - Kvartalsrapport 2013-Q1
2013-02-12 - Bokslutskommuniké 2012
2012-10-26 - Kvartalsrapport 2012-Q3
2012-08-17 - Kvartalsrapport 2012-Q2
2012-04-27 - X-dag ordinarie utdelning BIOT 0.40 SEK
2012-04-26 - Kvartalsrapport 2012-Q1
2012-04-26 - Årsstämma
2012-02-09 - Bokslutskommuniké 2011
2011-10-26 - Kvartalsrapport 2011-Q3
2011-08-17 - Kvartalsrapport 2011-Q2
2011-04-28 - X-dag ordinarie utdelning BIOT 0.25 SEK
2011-04-27 - Årsstämma
2011-04-27 - Kvartalsrapport 2011-Q1
2011-02-10 - Bokslutskommuniké 2010
2010-10-26 - Kvartalsrapport 2010-Q3
2010-08-13 - Kvartalsrapport 2010-Q2
2010-04-30 - X-dag ordinarie utdelning BIOT 0.20 SEK
2010-04-29 - Kvartalsrapport 2010-Q1
2010-02-11 - Bokslutskommuniké 2009
2009-10-27 - Kvartalsrapport 2009-Q3
2009-08-14 - Kvartalsrapport 2009-Q2
2009-04-28 - X-dag ordinarie utdelning BIOT 0.20 SEK
2009-04-27 - Kvartalsrapport 2009-Q1
2009-04-27 - Årsstämma

Beskrivning

LandSverige
ListaLarge Cap Stockholm
SektorHälsovård
IndustriMedicinteknik
Biotage är verksamt inom bioteknik. Bolaget tillhandahåller lösningar inom kromatografi, organisk syntes och provberedning. Bolaget har verksamhet på global nivå, främst koncentrerat till Europa, Nordamerika och Asien och en stor del av projekten bedrivs även i samarbete med övriga aktörer inom nämnd marknad. Kunderna återfinns inom vård och omsorg, samt inom livsmedelsindustrin.
2023-06-01 21:15:00

Uppsala, Sweden – 1 June 2023 – Biotage AB (publ) (“Biotage”) has today completed the acquisition of Astrea Bioseparations (“Astrea”), which was announced on 15 February 2023. As part of the completion, the board of directors of Biotage has, by virtue of an authorization granted by the Annual General Meeting held on 27 April 2023, resolved to issue 13,954,103 ordinary shares to the Sellers (as defined below).

As previously announced, Biotage has entered into agreements to acquire all of the shares in Astrea from Gamma Biosciences (“Gamma”) [1], a life sciences tools platform created by KKR. The acquisition also includes the shares held by certain minority investors [2] in the Astrea group (together with Gamma, the “Sellers”, and together with the acquisition of Astrea, the “Transaction”). The purchase price amounts to approximately MUSD 215 (approximately MSEK 2,233 [3]) (excluding closing adjustments and potential milestone-based payments and including a capital injection to be used by Biotage to pay off debt in Astrea related to Astrea’s recent acquisition of Delta Precision Ltd, as well as for further investments in the acquired business). The purchase price (excluding any closing adjustments and milestone-based payments) will be paid in new ordinary shares in Biotage. Any closing adjustments and milestone-based payments will be settled in cash. The milestone-based payments comprise a maximum of approximately MUSD 45 (approximately MSEK 467), which will be settled over three years based upon achievement of certain revenue and gross profit goals.

The board of directors has today resolved to issue the consideration shares to the Sellers, comprising of ordinary shares in Biotage, as part of the Transaction. The share issue will increase the total number of shares in Biotage from 66,713,592 to 80,667,695, entailing an increase in the share capital of SEK 19,396,203.17. The share issue will result in a dilution of approximately 17.5 percent of the current number of shares and votes [4] in Biotage. The number of consideration shares issued to the Sellers, comprising of ordinary shares in Biotage, has been determined based on an agreed share price of SEK 160 per ordinary share, based on negotiations between the board of directors of Biotage and the Sellers on arm’s length.

Furthermore, Gamma has entered into lock-up undertakings in favour of Biotage, with customary exceptions, not to sell its holdings for a period of the shorter of (a) two years from the date of the completion of the Transaction and (b) as long as Gamma has two representatives appointed as board members of Biotage. [5]

Biotage has received regulatory approval from the UK Secretary of State for Business, Energy and Industrial Strategy for the Transaction. Kieran Murphy and Kugan Sathiyanandarajah, elected as board members at the Annual General Meeting held on 27 April 2023 conditional upon the completion of the Transaction, will accede as board members of Biotage as of today.

About Biotage

Biotage is a Global Impact Tech Company committed to solving society’s problems. We offer workflow solutions and products to customers in drug discovery and development and diagnostics, analytical testing and water and environmental testing.

Biotage is contributing to sustainable science with the goal to make the world a healthier, greener and cleaner place – HumanKind Unlimited.

Our customers span a broad range of market segments including pharmaceutical, biotech, diagnostic, contract research and contract manufacturers as well as clinical, forensic and academic laboratories in addition to organizations focused on food safety, clean water and environmental sustainability.

Biotage is headquartered in Uppsala in Sweden and employs over 500 people worldwide. The Group had sales of 1,566 MSEK in 2022 and our products are sold in more than 80 countries. Biotage’s share (BIOT) is listed in the Large Cap segment on the NASDAQ Stockholm.
Website: www.biotage.com

Contacts
Tomas Blomquist, President and CEO
Tel: 0705 23 01 63, tomas.blomquist@biotage.com

The information was submitted for publication, through the agency of the contact person set out above, at 2023-06-01 21:15 CEST.

[1] Held through Gamma Biosciences Newco Limited and Gamma Biosciences Newco 2 Limited, two entities controlled by KKR.
[2] Held through Nano Hold Co., LLC.
[3] Based on an exchange rate SEK/USD of 10.38445, used throughout this press release for the conversion of USD/SEK.
[4] Excluding 729,817 Class C shares in Biotage held in treasury by Biotage.
[5] With respect to (b), such shorter time period is only applicable if (i) Gamma has voted for re-election or new election, as applicable, of the representatives and (ii) none of the representatives have resigned by way of own decision.